Schilke Tobin — SEC insider filings
SEC reporting owner CIK 1678984. 42 insider filings on record with FilingPulse; latest filed 2026-11-17.
Transaction summary — filings shown
Covers all 42 filings on record, filed 2020-10-02 to 2026-11-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 15 legs across 12 filings — 78,399 shares, $2,332,290 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 48.
- Largest priced transaction: sale of 21,401 shares @ $34.55 ($739,338) in Revance Therapeutics, Inc., filed 2023-05-16.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Revance Therapeutics, Inc. (RVNC) | CFO | 35 | — | 14 legs · 71,686 sh · $2,065,985 | 38 |
| Crinetics Pharmaceuticals, Inc. (CRNX) | Chief Financial & Infra. Ofcr. | 5 | — | 1 leg · 6,713 sh · $266,305 | 9 |
| Lexeo Therapeutics, Inc. (LXEO) | Director | 2 | — | — | 1 |
Insider filings — Schilke Tobin
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-17 | 3 | Lexeo Therapeutics, Inc. (LXEO) | Holdings only — no transactions reported | EDGAR |
| 2026-11-17 | 4 | Lexeo Therapeutics, Inc. (LXEO) | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2026-09-01 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Disposition to issuer (D): 7,956 @ $85 · Disposition to issuer (D): 71,471 @ $85 · Disposition to issuer (D): 80,000 (derivative) @ $51.25 · Disposition to issuer (D): 50,000 (derivative) @ $41.21 | EDGAR |
| 2026-08-24 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Grant/award (A): 471 @ $0 | EDGAR |
| 2026-03-04 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Sale (S): 6,713 @ $39.67 | EDGAR |
| 2026-02-25 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Grant/award (A): 32,000 @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Grant/award (A): 52,000 @ $0 · Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2025-02-06 | 4 | Revance Therapeutics, Inc. (RVNC) | Code (U): 97,999 @ $3.65 · Disposition to issuer (D): 103,555 · Grant/award (A): 20,883 @ $0 · Disposition to issuer (D): 20,883 | EDGAR |
| 2025-02-05 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 6,888 @ $0 | EDGAR |
| 2025-01-03 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 1,000 @ $2.18 | EDGAR |
| 2024-07-02 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 1,000 @ $2.18 | EDGAR |
| 2024-03-19 | 4 | Revance Therapeutics, Inc. (RVNC) | Tax withholding (F): 3,822 @ $5.30 · Sale (S): 9,361 @ $5.04 | EDGAR |
| 2024-03-04 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 17,447 @ $0 | EDGAR |
| 2024-02-02 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 96,667 @ $0 · Grant/award (A): 145,001 (derivative) @ $0 | EDGAR |
| 2024-01-03 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 434 @ $7.47 | EDGAR |
| 2023-08-15 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 22,620 @ $0 · Tax withholding (F): 11,215 @ $18.91 | EDGAR |
| 2023-07-05 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 769 @ $15.61 · Sale (S): 1,701 @ $25.04 | EDGAR |
| 2023-06-05 | 4 | Revance Therapeutics, Inc. (RVNC) | Sale (S): 2,701 @ $30.57 · Sale (S): 500 @ $31 | EDGAR |
| 2023-05-16 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 42,349 @ $0 · Sale (S): 21,401 @ $34.55 | EDGAR |
| 2023-05-02 | 4 | Revance Therapeutics, Inc. (RVNC) | Sale (S): 3,201 @ $31.70 | EDGAR |
| 2023-04-04 | 4 | Revance Therapeutics, Inc. (RVNC) | Sale (S): 3,201 @ $32.15 | EDGAR |
| 2023-03-17 | 4 | Revance Therapeutics, Inc. (RVNC) | Tax withholding (F): 3,739 @ $30.65 | EDGAR |
| 2023-03-09 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 42,349 @ $0 · Sale (S): 18,517 @ $31.59 | EDGAR |
| 2023-03-02 | 4 | Revance Therapeutics, Inc. (RVNC) | Sale (S): 3,201 @ $33.50 | EDGAR |
| 2023-02-16 | 4 | Revance Therapeutics, Inc. (RVNC) | Tax withholding (F): 2,085 @ $33.21 | EDGAR |
| 2023-02-02 | 4 | Revance Therapeutics, Inc. (RVNC) | Sale (S): 3,201 @ $34.60 · Grant/award (A): 50,435 (derivative) @ $0 | EDGAR |
| 2023-01-23 | 4 | Revance Therapeutics, Inc. (RVNC) | Sale (S): 1,000 @ $31 | EDGAR |
| 2023-01-10 | 4 | Revance Therapeutics, Inc. (RVNC) | Sale (S): 1,701 @ $25 · Sale (S): 1,000 @ $28 · Sale (S): 1,000 @ $30 | EDGAR |
| 2023-01-03 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 645 @ $12.18 | EDGAR |
| 2022-12-16 | 4 | Revance Therapeutics, Inc. (RVNC) | Tax withholding (F): 1,557 @ $21.50 | EDGAR |
| 2022-07-05 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 965 @ $11.75 | EDGAR |
| 2022-03-17 | 4 | Revance Therapeutics, Inc. (RVNC) | Tax withholding (F): 2,607 @ $15.79 | EDGAR |
| 2022-02-17 | 4 | Revance Therapeutics, Inc. (RVNC) | Tax withholding (F): 2,241 @ $13.35 · Tax withholding (F): 683 @ $13.35 | EDGAR |
| 2022-02-04 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 68,093 (derivative) @ $0 | EDGAR |
| 2022-01-04 | 4 | Revance Therapeutics, Inc. (RVNC) | Other (J): 404 @ $13.87 | EDGAR |
| 2021-12-17 | 4 | Revance Therapeutics, Inc. (RVNC) | Tax withholding (F): 1,556 @ $15.92 | EDGAR |
| 2021-07-02 | 4 | Revance Therapeutics, Inc. (RVNC) | Other (J): 446 @ $24.09 | EDGAR |
| 2021-02-19 | 4 | Revance Therapeutics, Inc. (RVNC) | Tax withholding (F): 684 @ $28.97 · Tax withholding (F): 1,973 @ $28.97 | EDGAR |
| 2021-02-04 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 22,620 @ $0 · Grant/award (A): 40,925 (derivative) @ $0 | EDGAR |
| 2021-01-04 | 4 | Revance Therapeutics, Inc. (RVNC) | Other (J): 493 @ $21.36 | EDGAR |
| 2020-12-22 | 4 | Revance Therapeutics, Inc. (RVNC) | Tax withholding (F): 1,556 @ $26.75 | EDGAR |
| 2020-10-02 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 15,750 @ $0 · Tax withholding (F): 5,446 @ $25.14 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-28 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1678984 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs